Figure 8.

A, Confocal micrographs of footpad sections immunolabeled against PGP9.5 and NF200 in samples of intact controls, and vehicle- and bumetanide-treated rats at 60 DPI. The density of regenerated nerve profiles in the subepidermal plexus was more abundant in vehicle-treated rats than in bumetanide-treated rats. The presence of NF200+ profiles was also lower in bumetanide-treated rats. There were a few small fibers entering the epidermis, where an increased number of Langerhans cells, positive for PGP9.5, was observed at 2 months after sciatic nerve injury. B, Measurement of the integrated density of immunolabeling for PGP9.5 and NF200 in the footpad. Significantly lower values were found in bumetanide-treated rats compared with the vehicle-treated rats (*p < 0.001 vs control; &p < 0.001 vs vehicle). C, Counts of IENFs labeled for PGP9.5 (*p < 0.001 vs control). Scale bar, 100 μm. Data are presented as the mean ± SEM.